Page last updated: 2024-12-08

4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID483407
CHEMBL ID425618
CHEBI ID94963
SCHEMBL ID334506
SCHEMBL ID10077667

Synonyms (27)

Synonym
AB01274748-01
4,4-difluoro-n-[(1s)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
NCGC00242513-01
BCP9000895
CHEMBL425618
BCPP000171
S2003
BRD-A04352665-001-01-2
CCG-221373
SCHEMBL334506
4,4-difluoro-n-[(1s)-3-[3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide
n-{(s)-3-[3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo-[3.2.1]octan-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide
SCHEMBL10077667
4,4-difluoro-n-{(1s)-3-[3-(3-isopropyl- 5-methyl-4h-1,2,4-triazol-4-yl)- 8-azabicyclo[3.2.1]oct-8-yl]-1- phenylpropyl}cyclohexanecarboxamide
AKOS024457791
AB01274748_02
us9107954, maraviroc
bdbm160935
CHEBI:94963
NCGC00242513-03
SW219829-1
4,4-difluoro-n-[(1s)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
Q27166728
BRD-A04352665-001-02-0
NCGC00242513-02
EN300-19671353
4,4-difluoro-n-[(1s)-3-{3-[3-methyl-5-(propan-2-yl)-4h-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexane-1-carboxamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tropane alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.31740.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency21.31740.00108.379861.1304AID1645840
tyrosine-protein kinase YesHomo sapiens (human)Potency34.49930.00005.018279.2586AID686947
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1506662Antiviral activity against VSV G SVA.MLV#922 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506672Toxicity in human TZM-bl cells assessed as reduction in cell proliferation at 10 uM incubated for 48 hrs by trypan blue staining based assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506670Antiviral activity against VSV G SVA.MLV#922 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506669Antiviral activity against CCR5-dependent HIV1 cladC isolate ZM214 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506665Antiviral activity against CCR5-dependent HIV1 clade B isolate QH0692 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506671Antiviral activity against CXCR4-dependent HIV1 HXB2 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506658Antiviral activity against CCR5-dependent HIV1 clade B isolate 6535 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506656Antiviral activity against CCR5-dependent HIV1 SF162 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506667Antiviral activity against CCR5-dependent HIV1 clade B isolate PVO infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506668Antiviral activity against CCR5-dependent HIV1 clade B isolate AC10 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506663Antiviral activity against CXCR4-dependent HIV1 HXB2 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506666Antiviral activity against CCR5-dependent HIV1 clade B isolate 6535 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506659Antiviral activity against CCR5-dependent HIV1 clade B isolate PVO infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506661Antiviral activity against CCR5-dependent HIV1 cladC isolate ZM214 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506664Antiviral activity against CCR5-dependent HIV1 SF162 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 72 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506660Antiviral activity against CCR5-dependent HIV1 clade B isolate AC10 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1812648Anti-HIV activity against HIV-1 NL4.3 infected in PHA-stimulated human PBMC expressing CXCR-4 assessed as inhibition of virus-indued cytopathogenic effect measured after 10 days by ELISA
AID1812649Anti-HIV activity against HIV-1 Ba-L infected in PHA-stimulated PBMC expressing CCR5 assessed as inhibition of virus-indued cytopathogenic effect measured after 10 days by ELISA
AID1506657Antiviral activity against CCR5-dependent HIV1 clade B isolate QH0692 infected in human TZM-bl cells assessed as reduction in virus infection incubated for 48 hrs by luciferase reporter gene based viral neutralization assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
AID1506673Toxicity in human TZM-bl cells assessed as reduction in cell proliferation at 10 uM incubated for 72 hrs by trypan blue staining based assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]